Skip to content

Not yet independently audited

This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.

Chronic kidney disease — master index

Last curated: 2026-11-01 (periodic literature sweep by Grok) · status: 11 curated pages, 13 draft pages · 24 planned pages · 24 built · 329 unique PubMed records cited in the wiki (348 in the bibliography) · 52 ClinicalTrials.gov identifiers cited in the wiki (54 across the condition) · 5 landmark notes. This sweep updated six already-draft wiki pages. FIND-CKD entered the KDIGO 2027 public-review draft as a 2B suggestion; atacicept and sibeprenlimab now have abstract-verified 24-month eGFR-slope results; an ADPKD empagliflozin feasibility trial found faster total-kidney-volume growth than placebo.

The condition in five sentences. CKD is persistent kidney structural or functional abnormality, staged by cause, GFR and albuminuria because both eGFR and uACR independently grade kidney, cardiovascular and mortality risk (KDIGO 2024, PMID 38490803; CKD Prognosis Consortium 2023, PMID 37787795). GBD 2023 estimates 788 million adults with CKD and an age-standardised adult prevalence of 14.2%, making it the ninth leading cause of death worldwide — yet lifetime risk of treated kidney failure is about 1 in 32 men and 1 in 71 women, and the distance between those two numbers is where most clinical judgement in this condition lives (PMIDs: 41213283, 32040656). Race-free eGFR equations changed classification and unmasked a high-risk subgroup, while simultaneously pushing more Black patients below trial-eligibility floors — a reform whose net effect on any patient-important outcome remains unmeasured (PMIDs: 34554658, 36069064, 39100866, 36606692). Interventions that alter glomerular haemodynamics have almost all succeeded (SGLT2 inhibition reduces progression by 37% across 90,409 randomized participants) while interventions that correct the biochemistry of advanced CKD — PTH, phosphate, vitamin D, haemoglobin, potassium — have almost all failed (PMIDs: 36351458, 23121374, 34003226, 22337679, 19880844, 40618849). With a median global supply of 11.75 nephrologists per million population, the binding constraint on outcomes is now conversion and delivery rather than efficacy (PMID 39235198).

Start here: overview. Research frontier: OPEN-QUESTIONS.md. Growth history: LOG.md.

Scope and borders

  • Owns CKD definition, cause, progression, prognosis, complications, kidney-directed therapy, kidney replacement decisions, conservative care and patient experience.
  • Dialysis technique and transplant immunology each receive decision-and-outcome treatment only; modality engineering, access technique and immunosuppression protocols are excluded.
  • The diabetic-kidney-disease page owns kidney endpoints and links the diabetes conditions; it does not reproduce glycaemic management.
  • Blood pressure as exposure, its measurement, targets and general drug choice belong to hypertension; CKD owns kidney outcomes.
  • AKI-to-CKD transition appears in progression; AKI is not built as a condition here.

Reading paths

New to CKD

  1. Overview
  2. Definition, staging and measurement
  3. Causes and aetiology
  4. Risk prediction and prognosis

Disease-modifying therapy

  1. RAS blockade and kidney outcomes
  2. SGLT2 inhibitors
  3. Mineralocorticoid receptor antagonists
  4. GLP-1 and emerging therapy
  5. Diabetic kidney disease

Advanced disease decisions

  1. Risk prediction
  2. Kidney replacement therapy decisions
  3. Conservative and supportive care
  4. Symptom burden and patient experience
  5. Red flags and safety concerns

Evidence and policy

  1. Guidelines synthesis
  2. Clinical trials landscape
  3. Statistics
  4. Bibliography
  5. Open questions

Pages

# File Scope Status Verified PMID records
1 overview.md Chronic kidney disease — Overview curated 54
2 definition-staging-and-measurement.md Definition, staging and measurement draft 44
3 epidemiology-and-burden.md Epidemiology and burden curated 37
4 causes-and-aetiology.md Causes and aetiology curated 40
5 race-and-the-egfr-equation.md Race and the eGFR equation curated 34
6 pathophysiology-and-progression.md Pathophysiology and progression draft 40
7 risk-prediction-and-prognosis.md Risk prediction and prognosis draft 38
8 ras-blockade-and-blood-pressure.md RAS blockade and kidney outcomes curated 36
9 sglt2-inhibitors.md SGLT2 inhibitors draft 37
10 mineralocorticoid-receptor-antagonists.md Mineralocorticoid receptor antagonists draft 40
11 glp1-and-emerging-therapy.md GLP-1 receptor agonists and emerging therapy draft 36
12 anaemia-of-ckd.md Anaemia of chronic kidney disease draft 32
13 mineral-and-bone-disorder.md CKD mineral and bone disorder curated 29
14 cardiovascular-risk-in-ckd.md Cardiovascular risk in CKD curated 35
15 potassium-acidosis-and-metabolic.md Potassium, acidosis and metabolic complications curated 31
16 diet-and-nutrition.md Diet and nutrition curated 34
17 diabetic-kidney-disease.md Diabetic kidney disease curated 35
18 inherited-and-glomerular-disease.md Inherited and glomerular disease draft 42
19 kidney-replacement-therapy-decisions.md Kidney replacement therapy decisions draft 35
20 conservative-and-supportive-care.md Conservative and supportive kidney care draft 31
21 symptom-burden-and-patient-experience.md Symptom burden and patient experience curated 34
22 guidelines.md Clinical practice guidelines draft 51
23 clinical-trials-landscape.md Clinical trials landscape draft 50
24 red-flags-and-safety-concerns.md Red flags and safety concerns draft 35

Literature layer

Layer File(s) State
Master bibliography BIBLIOGRAPHY.md 348 unique PubMed records after the 2026-11-01 sweep
Landmark notes notes/ 5 notes: DAPA-CKD, EMPA-KIDNEY, race-free eGFR, IDEAL, FLOW (one mis-attributed PMID corrected at audit)
Guideline registry REGISTRY.md 28 entries, including the 2027 CKD medications public-review draft (recommendation-level text now read) and an American Society of Onconephrology anaemia position statement
Statistics STATISTICS.md Burden, measurement, outcomes and safety tables; 2026-11-01 adds abstract-verified IgAN slope/composite rows and the ADPKD empagliflozin TKV signal
Patient voice method README.md ethics and method documented
Patient organizations organizations.md 11 verified public organizations/campaigns
Patient themes themes.md 8 themes, each supported by at least two sources
Patient sources sources.md annotated inventory with coverage limits

Status note

Built by codex; independently audited by Claude on 2026-09-02; then deepened by Claude and independently re-audited by Codex on 2026-09-02. Periodic literature sweep by Grok on 2026-10-11 added 11 PubMed records (including two pre-window stale absences: TELIGAN and MIRO-CKD) and four NCT identifiers. Periodic literature sweep by Claude on 2026-10-18 added 2 wiki-cited PubMed records (the 2026 Cochrane convective-dialysis update and a DAPA-CKD Klinrisk validation), 7 bibliography- or registry-only records, and corrected two stale ClinicalTrials.gov primary-completion dates. The Codex sweep on 2026-10-25 added 15 bibliography records, verified VIDEO-KD against full text and Table 2, flagged four new phase 3 IgAN publications without importing abstract-only effect estimates, updated DEAK, and catalogued KDIGO draft/final status. The Grok sweep on 2026-11-01 read the KDIGO 2027 public-review draft PDF (FIND-CKD as Rec 1.2.3, 2B), imported abstract-verified IgAN slope and composite figures, and added the ADPKD empagliflozin TKV feasibility result. An auditor from a different engine must review it.

11 pages remain curated; 13 are draft. The 2026-10-25 sweep demoted conservative care and SGLT2 inhibitors. Other draft statuses include the earlier sweeps and the two pre-existing verification limitations below.

Two pages carry a separate, pre-existing reason for draft status that the deepening pass did not resolve:

  • guidelines.md — it synthesizes what guideline documents recommend, and two of its central sources (KDIGO 2024 full guideline, PMID 38490803; KDIGO 2017 CKD-MBD update, PMID 30675420) carry no PubMed abstract, so those characterizations could not be checked against retrievable source text. The document-level facts it asserts — publication and review dates, supersession chains, URLs — were verified live. The deepening pass added the 2026 AHA/ACC/ADA/ASN CKM guideline and ADA Standards §11, both of which have retrievable records.
  • red-flags-and-safety-concerns.md — its trial-derived material is fully verified, but the opening red-flag list and the medication-reconciliation guidance rest on the same non-retrievable KDIGO full text.

See LOG.md for the full curation history and the current sweep’s retrieval limits and follow-ups.